Medicalgorithmics (FRA:B8E) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:B8E Medicalgorithmics SA FRA:B8E
70 GF Score
Price €5.95
GF Value €6.25
! 4 Warning Signs
View Full Analysis

What is Medicalgorithmics FFO?

FFO (Funds from operations) only applies to REITs.

FRA:B8E
70GF Score
Medicalgorithmics SA FRA:B8E
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Medicalgorithmics (FRA:B8E) Overvalued in 2026?

Based on GuruFocus' analysis, Medicalgorithmics stock appears to be undervalued. The current stock price of €5.95 is trading 4.8% below its estimated GF Value™ of €6.25.

Key valuation signals for FRA:B8E:

  • FFO:
  • GF Value™: €6.25 vs. price of €5.95 (4.8% below fair value)
  • GF Score™: 70/100 with 4 warning signs

No single metric tells the full story. See the FRA:B8E stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medicalgorithmics Business Description

Other Exchanges MDG:Poland
Address Al Jerozolimskie 81, 19 Floor, Central Tower Building, Warsaw, POL, 02-001
Medicalgorithmics SA is a medical technology company. It is engaged in the development of Digital Signal Processing (DSP) algorithms development and software and hardware electronics design for medical applications. The company specializes in providing advance technological solutions in the field of cardiac diagnostics, with a particular focus on ECG signal analysis. The group concentrates on the production and development of its flagship product Pocket ECG - a system for remote monitoring of cardiac arrhythmias. The offered solutions include algorithms and diagnostic systems used in remote heart monitoring. The company operates in Poland, the USA, and other, with majority of revenue from the USA.
70GF Score

Get the complete analysis for FRA:B8E

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.95
Price
€6.25
GF Value